Skip to main content
Top
Published in: Familial Cancer 1/2014

01-03-2014 | Original Article

Impact of breast cancer family history on tumor detection and tumor size in women newly-diagnosed with invasive breast cancer

Authors: Fabienne Dominique Schwab, Nicole Bürki, Dorothy Jane Huang, Viola Heinzelmann-Schwarz, Seraina Margaretha Schmid, Marcus Vetter, Andreas Schötzau, Uwe Güth

Published in: Familial Cancer | Issue 1/2014

Login to get access

Abstract

This study evaluated the impact of family history (FH) on tumor detection, the patient’s age and tumor size at diagnosis in breast cancer (BC). Furthermore, we investigated whether the impact of FH on these features was dependent on degree of relationship, number of relatives with a BC history, or the age of the affected relative at the time that her BC was diagnosed. Out of the entire cohort (n = 1,037), 244 patients (23.5 %) had a positive FH; 159 (15.3 %) had first-degree relatives affected with BC and 85 patients (8.2 %) had second-degree affected relatives. Compared to women who had no BC-affected relatives, the tumors of women who had positive FH were more often found by radiological breast examination (RBE: 31.7 %/27.2 %, p = 0.008), and they were smaller (general tumor size: 21.8 mm/26.4 mm, p = 0.003; size of tumors found by breast self-examination (BSE): 26.1 mm/30.6 mm, p = 0.041). However, this positive effect of increased use of BC screening and smaller tumor sizes was only observed in patients whose first-degree relatives were affected (comparison with second-degree affected relatives: RBE: 43.8 %/24.7 %; odds ratio 2.38, p = 0.007; general tumor size: 19.3 mm/26.3 mm; mean difference (MD) −6.9, p = 0.025; tumor size found by BSE: 22.5 mm/31.0 mm; MD −8.5, p = 0.044). When more second-degree relatives or older relatives were diagnosed with BC, the tumors of these patients were similarly often detected by RBE (relationship: 24.7 %/27.2 %, p = 0.641; age: 33.7 %/27.2 %, p = 0.177) and had similar tumor sizes (general size: 26.3 mm/26.4 mm, p = 0.960; BSE: 31.0 mm/30.6 mm, p = 0.902) as those of women without a FH. Women with a positive FH generally use mammography screening more often and perceive changes in the breast earlier than women without such history. The increased awareness of BC risk decreases if the relationship is more distant.
Literature
1.
go back to reference Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358(9291):1389–1399CrossRef Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358(9291):1389–1399CrossRef
2.
go back to reference Colditz GA, Kaphingst KA, Hankinson SE, Rosner B (2012) Family history and risk of breast cancer: nurses’ health study. Breast Cancer Res Treat 133(3):1097–1104PubMedCentralPubMedCrossRef Colditz GA, Kaphingst KA, Hankinson SE, Rosner B (2012) Family history and risk of breast cancer: nurses’ health study. Breast Cancer Res Treat 133(3):1097–1104PubMedCentralPubMedCrossRef
3.
go back to reference Couto E, Banks E, Reeves G, Pirie K, Beral V (2008) Family history and breast cancer tumour characteristics in screened women. Int J Cancer 123(12):2950–2954PubMedCrossRef Couto E, Banks E, Reeves G, Pirie K, Beral V (2008) Family history and breast cancer tumour characteristics in screened women. Int J Cancer 123(12):2950–2954PubMedCrossRef
4.
go back to reference Murabito JM, Evans JC, Larson MG, Kreger BE, Splansky GL, Freund KM, Moskowitz MA, Wilson PW (2001) Family breast cancer history and mammography: Framingham offspring study. Am J Epidemiol 154(10):916–923PubMedCrossRef Murabito JM, Evans JC, Larson MG, Kreger BE, Splansky GL, Freund KM, Moskowitz MA, Wilson PW (2001) Family breast cancer history and mammography: Framingham offspring study. Am J Epidemiol 154(10):916–923PubMedCrossRef
5.
go back to reference Taplin S, Anderman C, Grothaus L (1989) Breast cancer risk and participation in mammographic screening. Am J Public Health 79(11):1494–1498PubMedCrossRef Taplin S, Anderman C, Grothaus L (1989) Breast cancer risk and participation in mammographic screening. Am J Public Health 79(11):1494–1498PubMedCrossRef
6.
go back to reference Tracy KA, Quillin JM, Wilson DB, Borzelleca J, Jones RM, McClish D, Bowen D, Bodurtha J (2008) The impact of family history of breast cancer and cancer death on women’s mammography practices and beliefs. Genet Med 10(8):621–625PubMedCrossRef Tracy KA, Quillin JM, Wilson DB, Borzelleca J, Jones RM, McClish D, Bowen D, Bodurtha J (2008) The impact of family history of breast cancer and cancer death on women’s mammography practices and beliefs. Genet Med 10(8):621–625PubMedCrossRef
7.
go back to reference Lijovic M, Davis SR, Fradkin P, Bradbury J, La China M, Schwarz M, Wolfe R, Farrugia H, Bell RJ (2009) The relationship between knowledge of family history and cancer characteristics at diagnosis in women newly-diagnosed with invasive breast cancer. Fam Cancer 8(4):299–305PubMedCrossRef Lijovic M, Davis SR, Fradkin P, Bradbury J, La China M, Schwarz M, Wolfe R, Farrugia H, Bell RJ (2009) The relationship between knowledge of family history and cancer characteristics at diagnosis in women newly-diagnosed with invasive breast cancer. Fam Cancer 8(4):299–305PubMedCrossRef
8.
go back to reference Malone KE, Daling JR, Doody DR, O’Brien C, Resler A, Ostrander EA, Porter PL (2011) Family history of breast cancer in relation to tumor characteristics and mortality in a population-based study of young women with invasive breast cancer. Cancer Epidemiol Biomarkers Prev 20(12):2560–2571PubMedCentralPubMedCrossRef Malone KE, Daling JR, Doody DR, O’Brien C, Resler A, Ostrander EA, Porter PL (2011) Family history of breast cancer in relation to tumor characteristics and mortality in a population-based study of young women with invasive breast cancer. Cancer Epidemiol Biomarkers Prev 20(12):2560–2571PubMedCentralPubMedCrossRef
9.
go back to reference Molino A, Giovannini M, Pedersini R, Frisinghelli M, Micciolo R, Mandara M, Pavarana M, Cetto GL (2004) Correlations between family history and cancer characteristics in 2256 breast cancer patients. Br J Cancer 91(1):96–98PubMedCentralPubMedCrossRef Molino A, Giovannini M, Pedersini R, Frisinghelli M, Micciolo R, Mandara M, Pavarana M, Cetto GL (2004) Correlations between family history and cancer characteristics in 2256 breast cancer patients. Br J Cancer 91(1):96–98PubMedCentralPubMedCrossRef
10.
go back to reference Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A (eds) (2009) AJCC cancer staging manual, 7th edn. Springer, New York Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A (eds) (2009) AJCC cancer staging manual, 7th edn. Springer, New York
11.
go back to reference Sobin L, Gospodarowicz M, Wittekind C (eds) (2009) UICC: TNM classification of malignant tumors, 7th edn. Blackwell, Oxford Sobin L, Gospodarowicz M, Wittekind C (eds) (2009) UICC: TNM classification of malignant tumors, 7th edn. Blackwell, Oxford
12.
go back to reference Sinicrope PS, Brockman TA, Patten CA, Frost MH, Vierkant RA, Petersen LR, Rock E, Clark LP, Vachon CM, Fredericksen ZS et al (2008) Factors associated with breast cancer prevention communication between mothers and daughters. J Womens Health (Larchmt) 17(6):1017–1023PubMedCentralCrossRef Sinicrope PS, Brockman TA, Patten CA, Frost MH, Vierkant RA, Petersen LR, Rock E, Clark LP, Vachon CM, Fredericksen ZS et al (2008) Factors associated with breast cancer prevention communication between mothers and daughters. J Womens Health (Larchmt) 17(6):1017–1023PubMedCentralCrossRef
13.
go back to reference Ochoa EM, Gomez-Acebo I, Rodriguez-Cundin P, Navarro-Cordoba M, Llorca J, Dierssen-Sotos T (2010) Relationship between family history of breast cancer and health-related behavior. Behav Med 36(4):123–129PubMedCrossRef Ochoa EM, Gomez-Acebo I, Rodriguez-Cundin P, Navarro-Cordoba M, Llorca J, Dierssen-Sotos T (2010) Relationship between family history of breast cancer and health-related behavior. Behav Med 36(4):123–129PubMedCrossRef
14.
go back to reference Phipps AI, Buist DS, Malone KE, Barlow WE, Porter PL, Kerlikowske K, Li CI (2011) Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk. Breast Cancer Res Treat 126(3):671–678PubMedCentralPubMedCrossRef Phipps AI, Buist DS, Malone KE, Barlow WE, Porter PL, Kerlikowske K, Li CI (2011) Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk. Breast Cancer Res Treat 126(3):671–678PubMedCentralPubMedCrossRef
15.
go back to reference Yoon PW, Scheuner MT, Jorgensen C, Khoury MJ (2009) Developing Family Healthware, a family history screening tool to prevent common chronic diseases. Prev Chronic Dis 6(1):A33PubMedCentralPubMed Yoon PW, Scheuner MT, Jorgensen C, Khoury MJ (2009) Developing Family Healthware, a family history screening tool to prevent common chronic diseases. Prev Chronic Dis 6(1):A33PubMedCentralPubMed
Metadata
Title
Impact of breast cancer family history on tumor detection and tumor size in women newly-diagnosed with invasive breast cancer
Authors
Fabienne Dominique Schwab
Nicole Bürki
Dorothy Jane Huang
Viola Heinzelmann-Schwarz
Seraina Margaretha Schmid
Marcus Vetter
Andreas Schötzau
Uwe Güth
Publication date
01-03-2014
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2014
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-013-9682-3

Other articles of this Issue 1/2014

Familial Cancer 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine